Analysts Gregg Gilbert and Gregory Fraser see no logic in Teva buying Mylan.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) does not need a big acquisition to maximize its earnings per share, or because a generic version of Copaxone has been approved, or because consolidation is taking place in generics, say Deutsche Bank analysts Gregg Gilbert and Gregory Fraser, referring to the headlines at the end of last week on a possible acquisition by Teva of Mylan.
The route to creating value for Teva shareholders does not necessarily lie through large acquisitions, Gilbert and Fraser say. While they see business logic in Mylan acquiring Perrigo, they see no such logic in an acquisition of Mylan by Teva.
Deustche Bank rates all three stocks "Buy", although the analysts acknowledge that they could come under short-term pressure.
Published by Globes [online], Israel business news - www.globes-online.com - on April 20, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015